The Correlation Between MicroRNAs in Serum and the Extent of Liver Injury
Abstract
To investigate the correlation between the absolute quantification of the microRNAs (miR-122, miR-451, miR-92a, miR-192) in serum during acute liver injury and the extent of liver injury on rat models of CCl4 induced acute liver injury and mice models of acetaminophen (APAP) induced acute liver injury. Furthermore, to investigate the correlation between the absolute quantification of microRNAs in serum and the drug induced liver injury pathological scoring system (DILI-PSS). Methods The acute liver injury model in rat by CCl4 (1.5 mL/kg), and the acute liver injury model in mice by APAP (160 mg/kg) were established. The serum at different time points on both models were collected respectively. The absolute quantification of microRNAs in serum were detected by using MiRbayTM SV miRNA Assay kit. Meanwhile, the pathological sections of liver tissue of the mice at each time point were collected to analyze the correlation between microRNAs and the degree of liver injury. Results In CCl4-induced rat acute liver injury model and APAP induced mouse acute liver injury, miR-122 and miR-192 appeared to be rising significantly, which remained the highest level at 24 h after treatment, and declined to the normal level after 72 h. In CCl4-induced rat acute liver injury model, the change of miR-92a was fluctuated and had no apparent rules, miR-451 declined gradually, but not obviously. In mice acute liver injury model induced by APAP, miR-92a and miR-451 in the progress of liver injury declined gradually, reached the lowest point at 48 h, and then recovered. The result of correlation analysis indicated that miR-122 and miR-192 presented a good positive correlation with the DILI-PSS ( r=0.741 3，P<0.05; r=0.788 3, P<0.01). Conclusion The absolute quantification of miR-122 and miR-192 in serum has the highest level in 24 h, then decrease in 72 h, in both drug-induced and chemical liver injury. In addition, both the two microRNAs have good correlation with DILI-PSS in APAP-induced liver injury models.
Keywords: Liver injury microRNAs, The absolute quantification, Correlation
Full Text:
PDFReferences
SLANKAMENAC К, BREITENSTEIN S, CLAVIEN PA, et al. Development and validation of a prediction score for postoperative acute renal failure following liver resection. Ann Surg,2009,250(5):720-728.
ZHANG Y, JIA Y. SUN SH, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem,2010,56(12): 1830-1838. VERMA S, KAPLOWITZ N. Diagnosis, management and prevention of drug-induced liver injury. Gut, 2009 , 58 ( 11 ): 1555-1564.
BARTEL DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.2004 ,116(2):281-297.
KASINSK1 AL, SLACK FJ. Epeigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer, 2011,11(12);849-864.
LI Z, RANTA TM. Therapeutic targeting of microRNAs; current status and future chanlleges. Nat Rev Drug Discov, 2014,13(8):622-638.
SHI Q. YANG X,MENDRICK DL. Hopes and challenges in using microRNAs as translational biomarkers in drug induced liver injury. Biomark Med,2013,7(2);307-315.
BALAS, PETRASEK J, MUNDKUR S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced and inflammatory liver diseases. Hepatology, 2012,56(5); 1946-1957.
ANTOINE DJ, DEAR JW. LEWIS PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology,2013,58(2) ;777-787.
WANG K, ZHANG S, MARZOLF B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A,2009,106( 11):4402-4407.
STARKEY LPJ, DEAR J, PLATT V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology,2011,54(5); 1767-1776.
HUANG JY, ZHANG K, CHEN DQ,et al. MicroRNA-451: epithelial mesenchymal transition inhibitors and prognostic biomarker of hepatocellularcarcinoma. Oncotarget, 2015, 6 (21):18613-18630.
YANG W, DOU C, WANG Y, et al. MicroRNA-92a contributes to tumor growth of human hepatocellular carcinoma by targeting FBXW7. Oncol Rep, 2015, 34 ( 5 ); 2576-2584.
XIE ХР, TANG F, YANG Z, et al. MicroRNA-derived fragment length polymorphism assay. Sci Rep,2015,5:9356. doi; 10. 1038/srep09356.
WATKINS PB, SELIGMAN PJ, PEARS JS, et al. Using controlled clinical trials to learn more about acute drug- induced liver injury. Hepatology,2008,48(5) : 1680-1689.
LEWIS JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol,2015,13( 12) :2173-2189.
RE VL, HAYNES K. FORDE KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy’s Law and a new prognostic model. Clin Gastroenterol Hepatol,2015,13(13);2360-2368.
KRAUSKOPF J, CAIMENT F, CLAESSEN SM. et al. Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-inducedliver injury. Toxicol Sci*2015,143(2):268-276.
CHURCH RJ. OTIENO M, MCDUFFIE JE, et al. Beyond miR-122; identification of microRNA alterations in blood during a time course of hepatobiliary injuryand biliary hyperplasia in rats. Toxicol Sci,2016 ,150(1) :3-14.
STARKEY LPJ, MERZ M, COUTTET P, et al. Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther,2012,92(3):291-293.
FANNIN RD. GERRISH K, SIEHER SO, et al. Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther,2016,99(4):432-441.
Refbacks
- There are currently no refbacks.
